Galinpepimut-S, a WT1-targeting immuno-oncology treatment, induces specific, robust and durable immune responses (IRs) in patients (Pts) with high-risk (HR) multiple myeloma (MM) Meeting Abstract
| Authors: | Koehne, G.; Devlin, S.; Korde, N.; Mailankody, S.; Heather, L.; Hassoun, H.; Lesokhin, A.; Lendvai, N.; Chung, D.; Sarlis, N.; Giralt, S.; Landgren, O. |
| Abstract Title: | Galinpepimut-S, a WT1-targeting immuno-oncology treatment, induces specific, robust and durable immune responses (IRs) in patients (Pts) with high-risk (HR) multiple myeloma (MM) |
| Meeting Title: | 5th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 17 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Sep 13-16 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-09-01 |
| Start Page: | S343 |
| End Page: | S344 |
| Language: | English |
| ACCESSION: | 124936166 |
| DOI: | 10.1016/j.clml.2017.07.164 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abstract: MM-252 -- Accession Number: 124936166 -- Entry Date: In Process -- Revision Date: 20170904 -- Publication Type: Article -- Supplement Title: Sep2017 Supplement 2 -- Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101525386. -- Source: cin20 |
Altmetric
Citation Impact
BMJ Impact Analytics
